

6th International Conference on

Clinical and Experimental Dermatology

May 04-06, 2016 Chicago, USA

**Iona Weir**

Decima Health Ltd, New Zealand

Atopis™ for the treatment of mild to moderate eczema

Atopis™, a topical natural cream, which has been developed to reduce the appearance and symptoms of eczema, a common inflammatory skin disease. Atopis™ contains Myriphytase™ extract which modulates the skin immune system by regulating IL-10, IL-17 and TNF- α cytokines. Myriphytase™ contains peptilipids™ and isomeric flavonoids which have antimicrobial, erythema, pruritus and wound healing properties. Two clinical trials have been successfully completed on Atopis™, the first open-label pilot study of 20 subjects and the second a double blinded placebo controlled clinical trial with 61 subjects. Both clinical trials recruited healthy subjects aged 18-75 years with mild to moderate eczema, which was determined at screening. Subjects topically applied Atopis™ twice daily for 30 days on areas identified with skin lesions and were followed to evaluate the efficacy of the Atopis™ in reducing the appearance of eczema lesions and reducing the symptoms of itching, scaling, and erythema. Dermatological assessments for severity and size of lesions and Severity Scoring of Atopic Dermatitis (SCORAD) demonstrated statistically significant reductions from baseline (20.61) to Day 30 (10.26) ($P < 0.04$) for the open label study. For the double blinded placebo controlled clinical trial, significant reductions from baseline (28.1) to Day 28 (17.5) for Atopis™ versus the placebo baseline (28.4) to (22.6) Day 28 ($P < 0.037$) were also found. Topical application of Atopis™ is effective for the treatment of mild to moderate eczema as it significantly reduced the appearance of lesions as well as symptoms associated including pruritis, scaling and erythema.

Biography

Iona Weir has completed her PhD at Auckland University and a sabbatical at the Ontario Cancer Institute. After 12 years as a Senior Scientist at Plant and Food Research Institute in New Zealand, she moved into the private sector where for the last 15 years, she was CSO and Director for several companies including BioDiscovery NZ Ltd, Lypanosys and Vital Food Processors Ltd. She is the Co-Founder and CEO of Decima Health Ltd, a New Zealand natural products biotechnology R&D company. She has published more than 30 papers in reputed journals and has 4 patents granted.

iona@decima.co.nz